Hoppensteadt DA - Search Results

1

Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization.

Iqbal O, Tobu M, Aziz S, Gerdisch M, Da Valle M, Demir M, Hoppensteadt DA, Ahmad S, Walenga JM, Fareed J. Iqbal O, et al. Among authors: da valle m, hoppensteadt da. J Card Surg. 2005 Jan-Feb;20(1):42-51. doi: 10.1111/j.0886-0440.2005.200316.x. J Card Surg. 2005. PMID: 15673409 Clinical Trial.

2

Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.

Demir M, Iqbal O, Untch B, Hoppensteadt DA, Gaikwad BS, Fareed J. Demir M, et al. Among authors: hoppensteadt da. Clin Appl Thromb Hemost. 2001 Jan;7(1):38-43. doi: 10.1177/107602960100700109. Clin Appl Thromb Hemost. 2001. PMID: 11190903 Free article.

3

Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin.

Hoppensteadt DA, Walenga JM, Fareed J. Hoppensteadt DA, et al. Semin Thromb Hemost. 1991;17 Suppl 1:60-4. Semin Thromb Hemost. 1991. PMID: 2068572

4

Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations.

Walenga JM, Pifarre R, Hoppensteadt DA, Fareed J. Walenga JM, et al. Among authors: hoppensteadt da. Semin Thromb Hemost. 1989 Jul;15(3):316-33. doi: 10.1055/s-2007-1002724. Semin Thromb Hemost. 1989. PMID: 2688104 Review. No abstract available.

5

TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.

Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. Hoppensteadt DA, et al. Thromb Res. 1995 Jan 15;77(2):175-85. doi: 10.1016/0049-3848(95)91623-s. Thromb Res. 1995. PMID: 7740509 Clinical Trial.

6

Evaluation of hematologic alterations associated with daily administration of low molecular weight heparin (Mono-Embolex) for a 12-week period.

Lojewski B, Bacher P, Iqbal O, Walenga JM, Hoppensteadt DA, Leya F, Fareed J. Lojewski B, et al. Among authors: hoppensteadt da. Semin Thromb Hemost. 1993;19 Suppl 1:36-43. Semin Thromb Hemost. 1993. PMID: 8395730

7

In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723.

Malinowska K, Iqbal O, Hoppensteadt DA, Walenga JM, Fareed J. Malinowska K, et al. Among authors: hoppensteadt da. Semin Thromb Hemost. 1993;19 Suppl 1:58-62. Semin Thromb Hemost. 1993. PMID: 8395732 No abstract available.

8

Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients.

Bacher P, Horst B, Breyer HG, Hoppensteadt DA, Walenga JM, Fareed J. Bacher P, et al. Among authors: hoppensteadt da. Semin Thromb Hemost. 1993;19 Suppl 1:73-8. Semin Thromb Hemost. 1993. PMID: 8395735 Clinical Trial.

9

Efficacy of pentasaccharide in a dog model of hemodialysis.

Hoppensteadt DA, Jeske WP, Walenga JM, Fu K, Yang LH, Ing T, Herbert JM, Fareed J. Hoppensteadt DA, et al. Thromb Res. 1997 Oct 15;88(2):159-70. doi: 10.1016/s0049-3848(97)00227-2. Thromb Res. 1997. PMID: 9361369

10

Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development.

Fareed J, Callas D, Hoppensteadt DA, Walenga JM, Bick RL. Fareed J, et al. Among authors: hoppensteadt da. Med Clin North Am. 1998 May;82(3):569-86. doi: 10.1016/s0025-7125(05)70011-0. Med Clin North Am. 1998. PMID: 9646780 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters